Lazarus 3D is using 3D printing to help advance surgeons' skills. Photo via laz3d.com

It is no surprise that, when a company offered life-like bladders for medical training, Houston urologists jumped at the opportunity — many had to learn the surgery by operating on bell peppers.

This sort of produce practice is the traditional method for teaching surgeons. Before a doctor ever makes an incision on a living person, they'll practice surgery on food — slicing bananas open and sewing grapes back together.

But for a pair of Baylor College of Medicine-educated doctors, that didn't seem like sufficient prep for working with living bodies; fruit surgery was not fruitful enough. In 2014, Drs. Jacques Zaneveld and Smriti Agrawal Zaneveld founded Lazarus3D to build a better training model — and layer by layer, they created models of abs and ribs and even hearts with a 3D printer.

"We adapted pre-existing 3D printing technology in a novel proprietary way that allows us to, overnight, build soft, silicone or hydrogel models of human anatomy," says Jacques, who serves as CEO. "They can be treated just like real tissue."

This isn't 3D printing's foray in medicine. In 1999, doctors in North Carolina implanted the first 3D-printed bladder in human bodies — they covered the synthetic organs in the patients' cells so that their bodies accepted them. Since, researchers have continued to find uses for the technology in the field, printing other organs and making prosthetic limbs.

But the Lazarus3D founders felt like medical training was lagging behind. Even cadavers, which medical schools also use to prepare doctors for surgery, don't represent a healthy human body or the diseased state of a hospital patient, said Smriti, who works as the research director.

The pair turned their kitchen into a printing lab and set to work, creating life-like models of human organs. They didn't have to go far after their first successes to find potential buyers — they just went to Starbucks. In a coffeeshop in the heart of the Medical Center, they talked loudly about their product until the neighborhood doctors and researchers took interest and gathered around.

Over the next few years, the Lazarus3D team pooled resources and contacts and, a summer after opening, they moved out of their kitchen and into an office. They now are a Capital Factory portfolio company and have partnerships with Texas Children's, Baylor College of Medicine, MD Anderson Cancer Center, and others, providing organs for specialized training — and the more they expand, the more they're able to prepare doctors for invasive, sometimes dangerous procedures.

"There are over 400,000 deaths annually in the U.S. due to medical error," Smriti says. "Not all of them are due to surgical mistakes, but all of these, nonetheless, were preventable."

The models can also be used for explaining to patients in a visual way what surgeries they're about to receive — the black and grey smears on an MRI scan might not actually help a patient understand much about what a surgeon is going to do to their body. In 2018, Lazarus3D won a contest with NASA on the potential for 3D printing organs in space, so that major surgeries might be performed there. And the printed organs can also be used by researchers to safely develop new surgery methods.

This year, the company grew to seven people and aims to expand even more to add to its sales and manufacturing teams. Having been funded mostly by friends and family investors, Lazarus3D plans enter its first equity round this year. They're raising $6 million.

"Every generation in medicine, people look back at what was done before and think 'Man, that was barbaric,'" Jacques said. "Fifty years from now, we're going to look back and think, 'Man, back then we used to just give someone a patient to learn how to do physical skills on? That seems crazy.'"

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston brain health co. secures $6.5M for rare disease study

neuro funding

Houston-based Goldenrod Therapeutics, part of Fannin Partners' portfolio, has announced the initial close of a $6.5 million series seed preferred stock round.

The round was led by Ataxia Ventures and an affiliate of Fannin, according to a news release.

Goldenrod Therapeutics plans to use the funding to support manufacturing, formulation optimization, IND-enabling studies and a Phase I study of its drug to treat brain inflammation, known as 11h.

The study will consider how 11h, which blocks the enzyme PDE4, could treat Friedreich’s ataxia (FA), a rare genetic disease that affects movement, speech and balance. To date, other PDE4 inhibitors have proven to regulate neuroinflammation and neuronal signaling, but have had adverse gastrointestinal side effects or have not reached enough of the central nervous system, according to Goldenrod.

The company says its 11h is expected to have "broad applicability" with limited emetric side effects.

“Our 11h program is a next-generation, orally bioavailable, brain-penetrant PDE4 inhibitor, where researchers overcame longstanding limitations associated with earlier PDE4 inhibitors," Dr. Dev Chatterjee, CEO of Goldenrod, said in the news release. "We believe this creates the potential for a best-in-class therapy for Friedreich’s Ataxia and a potential foundation for development across multiple neurodegenerative and neuroinflammatory disorders.”

11h was first developed at the University of Nebraska Medical Center (UNeMed). Houston-based Fannin Partners in-licensed the product 2020 and landed SBIR Phase I funding to support its initial development for opioid use disorder soon after.

Goldenrod has also received funding to study 11h's effectiveness for multiple sclerosis, methamphetamine addiction and cocaine addiction.

Goldenrod says it is developing 11h to target a variety of neurological and inflammatory conditions, including Alzheimer's disease, multiple sclerosis, ALS, substance use disorders, Batten disease, pain and traumatic brain injury.

27 Houston companies make Fortune 500 for 2026, led by energy giants

Houston HQs

Editor's note: This article has been updated to correct the number of companies based in the Dallas-Fort Worth area.

Houston is a giant among U.S. hubs for corporate headquarters.

The 2026 Fortune 500 lists 27 companies based in the Houston area, with many energy companies claiming top spots. Houston ties with Chicago for the second-most Fortune 500 headquarters, preceded only by New York City (53). Dallas-Fort Worth is home to 24 Fortune 500 headquarters.

Texas leads the nation for Fortune 500 headquarters (57), with California in the No. 2 spot and New York at No. 3.

“Texas is the undisputed headquarters of headquarters,” Gov. Greg Abbott said in a news release. “The world’s leading businesses invest with confidence in Texas because of our welcoming business climate, predictable regulatory environment, and skilled and growing workforce. People and businesses are choosing Texas because Texas works.”

The 2026 Fortune 500 ranks the largest U.S. corporations based on revenue in fiscal year 2025.

Here’s a rundown of the 27 Fortune 500 companies based in the Houston area.

  • No. 9 ExxonMobil
  • No. 21 Chevron
  • No. 29 Phillips 66
  • No.55 Sysco
  • No. 75 ConocoPhillips
  • No. 89 Enterprise Products Partners
  • No. 103 Plains GP Holdings
  • No. 133 Hewlett Packard Enterprise
  • No. 149 NRG Energy
  • No. 157 Quanta Services
  • No. 164 Baker Hughes
  • No. 173 Occidental Petroleum
  • No. 179 Waste Management
  • No. 201 EOG Resources
  • No. 204 Group 1 Automotive
  • No. 207 Halliburton
  • No. 223 Cheniere Energy
  • No. 236 Corebridge Financial
  • No. 262 Targa Resources
  • No. 266 Kinder Morgan
  • No. 388 Westlake
  • No. 435 CenterPoint Energy
  • No. 438 APA
  • No. 440 Comfort Systems USA
  • No. 455 NOV
  • No. 488 KBR
  • No. 496 Coterra Energy. Oklahoma City, Oklahoma-based Devon Energy and Houston-based Coterra Energy merged in early May, with the combined company retaining the Devon Energy name and the Houston headquarters.

The Greater Houston Partnership notes the Houston area soon will welcome its 28th Fortune 500 company. Expand Energy (formerly Chesapeake Energy), appearing at No. 362 on the 2026 list, says it’s moving its headquarters from Oklahoma City to Spring this year.

As the natural gas producer prepares to relocate to Texas, it’s hunting for a new leader. Nick Dell’Osso stepped down as president and CEO earlier this year. Board Chairman Michael Wichterich is interim president and CEO.

Dell’Osso became president and CEO of Oklahoma City-based Gulfport Energy effective May 28.

---

This article first appeared on EnergyCapitalHTX.com.